Fusobacteria use a Special Sugar-Binding Protein to Bind to Colon Tumors
News Aug 11, 2016
Some bacteria, called fusobacteria, commonly found in the mouth, use a sugar-binding protein to stick to developing colorectal polyps and cancers, according to a new study by researchers from Harvard T.H. Chan School of Public Health and Hebrew University-Hadassah School of Dental Medicine. While certain fusobacteria have previously been shown to worsen colorectal cancer in animals by the Garrett Lab at Harvard Chan School, this study is the first to demonstrate how they may get to and stick to developing tumors.
Understanding this mechanism is an important step toward fighting colorectal cancer, said co-senior study author Wendy Garrett, Melvin J. and Geraldine L. Glimcher Associate Professor of Immunology and Infectious Diseases at Harvard Chan School. It might inform ways of blocking fusobacteria from homing in on colorectal tumors, she said. “Alternatively, and perhaps more importantly, our findings suggest that drugs targeting the same or similar mechanisms of bacterial sugar-binding proteins could potentially prevent these bacteria from exacerbating colorectal cancer.”
Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and microbes have emerged as key factors that influence the development and progression of the disease.
Garrett and co-senior study author Gilad Bachrach of Hebrew University used human samples and mouse models to confirm their new findings on fusobacteria. Other Harvard Chan authors include Nora Ou and Caitlin Brennan.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018